(Q40573926)

21 September 2017

Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein (English)

1 reference

21 September 2017

1 reference

1 reference

8

1 reference

21 September 2017

10

Srdan Verstovsek

1 reference

21 September 2017

6

William G Wierda

1 reference

21 September 2017

7

Michael Andreeff

1 reference

21 September 2017

9

Kimberly Hayes

1 reference

21 September 2017

11

Hagop M Kantarjian

1 reference

21 September 2017

1

Barbara Scappini

1 reference

21 September 2017

2

Simona Gatto

1 reference

21 September 2017

3

Francesco Onida

1 reference

21 September 2017

4

Clara Ricci

1 reference

21 September 2017

5

Vladimir Divoky

1 reference

21 September 2017

Miloslav Beran

12

1 reference

PubMed ID

15042680

21 September 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

21 September 2017

1 reference

21 September 2017

100

1 reference

21 September 2017

1459-1471

1 reference

21 September 2017

7

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Cytogenetic and molecular mechanisms of resistance to imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Ph-positive chronic myeloid leukemia with near-haploid conversion in vivo and establishment of a continuously growing cell line with similar cytogenetic pattern.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Determination of cell fate by c-Abl activation in the response to DNA damage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

c-Abl: activation and nuclear targets

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Regulation of cell death by the Abl tyrosine kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20131

7 January 2021

Identifiers

DOI

10.1002/CNCR.20131

1 reference

release_fg2ohayozfdf3kbmla3pzvxyoy

21 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fg2ohayozfdf3kbmla3pzvxyoy

24 November 2022

mapped directly with Wikidata item

PubMed ID

15042680

1 reference

PubMed ID

15042680